The randomized, double-blind, placebo-controlled clinical trial studied 86 mildly hypercholesterolemic patients, age 35-70, with liver steatosis. They were given either 600mg/day of Bergacyn FF or a placebo. Overweight and obese subjects in both groups were assigned the task of reducing their intake by 400-500 calories per day.
The study found that liver fat accumulation was reduced by 9% more in the test group than in the placebo group. Subjects over 50 years old saw an even greater reduction in liver fat—15%. A press release on the topic notes that the improvement was attributed solely to Bergacyn FF, not the dietary changes.
Related: Study Supports Bergacyn For Liver and Vascular Benefits DolCas Biotech Announces Zero-Waste Goal Study Uncovers How Fructose Affects Liver Health
Bergacyn FF is a clean-label blend of botanical extracts from bergamot and the wild Italian artichoke thistle leaf.“An unexpected outcome of the study was Bergacyn’s impact on weight loss,” said Dr. Shavon Jackson-Michel, Director of Medical & Scientific Affairs of DolCas Biotech, in the press release. “The absolute difference made by Bergacyn FF for body weight reductions over placebo was approximately 4 lbs. The total weight loss in the Bergacyn FF group over 12 weeks fell just under 10 lbs. The new research supports the traditional wisdom of botanical synergism and how standardized ingredient formulations could be the best way forward for multifactorial processes such as non-alcoholic fatty liver disease.”
